Finance JournalistFinance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
US Senator Elizabeth Warren has launched an inquiry into whether the Commodity Futures Trading Commission can effectively oversee cryptocurrency and prediction markets amid concerns about staffing reductions, enforcement declines and potential political influence.
Tokenised real-world assets continued to expand rapidly in 2026 despite a broader cryptocurrency market downturn, with active tokenised RWAs surging 589% since early 2025, according to Binance Research.
LTR Pharma (ASX:LTP) has secured a foothold in the United States by executing a binding term sheet with Shed Holdings.
The US House Ways and Means Committee is set to examine a series of cryptocurrency tax reform proposals on Tuesday as lawmakers continue broader efforts to establish a regulatory framework for digital assets.
Tianqi Lithium and IGO (ASX:IGO) are locked in a high-stakes standoff with the Australian Taxation Office.
Novo Nordisk (NYSE:NVO) announced that prescriptions for the oral version of Wegovy have exceeded 3 million since the product’s U.S. market introduction in January 2026.
Ingredion (NYSE:INGR) announced on Monday a definitive agreement to acquire the UK-based ingredients specialist Tate & Lyle in an all-cash transaction.
Alliance Resource Partners (NASDAQ:ARLP) announced on June 8, 2026, that it has entered into definitive agreements to acquire general partner and limited partner interests in AllDale Minerals III, LP and AllDale Minerals IV, LP (collectively, “AllDale III & IV”) for approximately $206.2 million.
FOX (NASDAQ:FOX) has finalized a multi-year agreement with the National Football League to serve as a broadcast partner for NFL content in Mexico.
Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.
